Eli Lilly reported positive Phase 3 trial results for Foundayo, highlighting a 16% lower risk of cardiovascular events compared to insulin. Novo Nordisk also recorded strong demand for Wegovy, with over 3 million prescriptions in its debut week. These positive developments boost confidence in both companies' weight-loss portfolios.